Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRAY-01: LY3537982 (olomorasib) + Pembrolizumab +/- Chemotherapy in First-Line KRAS G12C-Mutant Advanced NSCLC
NCT06119581Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 29
01
Overview
A Phase 3 trial of olomorasib in non-small cell lung cancer (NSCLC), sponsored by Eli Lilly and Company. Started Dec 2023; status: recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06119581.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119581.